psychiatryПСИХИАТРИЯPsychiatry (Moscow) (Psikhiatriya)1683-83192618-6667FSBSI “The Mental Health Research Centre”; LLC «Publisher «MIA»psychiatry-211Research ArticleМАТЕРИАЛЫ КОНФЕРЕНЦИИ МОЛОДЫХ УЧЕНЫХ, ПОСВЯЩЕННОЙ ПАМЯТИ АКАДЕМИКА АМН СССР А.В. СНЕЖНЕВСКОГО, 24 МАЯ 2016, МОСКВАИсследование прокогнитивных эффектов высокоселективного антагониста 5НТ-6 рецепторов у больных шизофренией в состоянии ремиссииПотанинСергей Сергеевичpotanin_ss@mail.ruРупчевГ. Е.noemail@neicon.ruБурминскийД. С.noemail@neicon.ruЛепилкинаТ. А.noemail@neicon.ruБениашвилиА. Г.noemail@neicon.ruМорозоваМ. А.noemail@neicon.ruФГБНУ «Научный центр психического здоровья»Russian Federation2016280920160717373Copyright © Потанин С.С., Рупчев Г.Е., Бурминский Д.С., Лепилкина Т.А., Бениашвили А.Г., Морозова М.А., 20162016Потанин С.С., Рупчев Г.Е., Бурминский Д.С., Лепилкина Т.А., Бениашвили А.Г., Морозова М.А.Потанин С.С., Рупчев Г.Е., Бурминский Д.С., Лепилкина Т.А., Бениашвили А.Г., Морозова М.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.journalpsychiatry.com/jour/article/view/211ReferencesSchaefer J., Giangrande E., Weinberger D.R., Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr. Res. 2013 Oct;150(1):42-50. DOI: 10.1016/j.schres.2013.07.009Schaefer J., Giangrande E., Weinberger D.R., Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr. Res. 2013 Oct;150(1):42-50. DOI: 10.1016/j.schres.2013.07.009Mazure C.M., Nelson J.C., Jatlow P.I., Bowers M.B. Jr. Drug-responsive symptoms during early neuroleptic treat- ment. Psychiatry Res. 1992 Feb;41(2):147-154. DOI: http://dx.DOI.org/10.1016/0165-781(92)90106-DMazure C.M., Nelson J.C., Jatlow P.I., Bowers M.B. Jr. Drug-responsive symptoms during early neuroleptic treat- ment. Psychiatry Res. 1992 Feb;41(2):147-154. DOI: http://dx.DOI.org/10.1016/0165-781(92)90106-DLeucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry. 2009 Apr;14(4):429-447. DOI: 10.1038/sj.mp.4002136Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry. 2009 Apr;14(4):429-447. DOI: 10.1038/sj.mp.4002136Glennon R.A. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J. Med. Chem. 2003 Jul 3;46(14):2795- 2812. DOI: 10.1021/jm030030nGlennon R.A. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J. Med. Chem. 2003 Jul 3;46(14):2795- 2812. DOI: 10.1021/jm030030nWest P.J., Marcy V.R., Marino M.J., Schaffhauser H. Activa- tion of the 5-HT(6) receptor attenuateslong-term potenti- ation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience. 2009 Dec 1;164(2):692-701. DOI: 10.1016/j.neuroscience.2009.07.061West P.J., Marcy V.R., Marino M.J., Schaffhauser H. Activa- tion of the 5-HT(6) receptor attenuateslong-term potenti- ation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience. 2009 Dec 1;164(2):692-701. DOI: 10.1016/j.neuroscience.2009.07.061de Foubert G., O'Neill M.J., Zetterström T.S. Acute onset by 5-HT(6)-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-as- sociated protein mRNA expression. Neuroscience. 2007 Jul 13;147(3):778-785. DOI: 10.1016/j.neuroscience.2007.04.045de Foubert G., O'Neill M.J., Zetterström T.S. Acute onset by 5-HT(6)-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-as- sociated protein mRNA expression. Neuroscience. 2007 Jul 13;147(3):778-785. DOI: 10.1016/j.neuroscience.2007.04.045Romero G., Sánchez E., Pujol M., Pérez P., Codony X., Ho- lenz J., Buschmann H., Pauwels P.J. Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways. Br. J. Pharma- col. 2006 Aug; 148(8):1133-1143. Epub 2006 Jul 24. DOI: 10.1038/sj.bjp.0706827Romero G., Sánchez E., Pujol M., Pérez P., Codony X., Ho- lenz J., Buschmann H., Pauwels P.J. Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways. Br. J. Pharma- col. 2006 Aug; 148(8):1133-1143. Epub 2006 Jul 24. DOI: 10.1038/sj.bjp.0706827Morozova M.A., Lepilkina T.A., Rupchev G.E., Beniashvi- ly A.G., Burminskiy D.S., Potanin S.S., Bondarenko E.V., Ka- zey V.I., Lavrovsky Y., Ivachtchenko A.V. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. CNS Spectr. 2014 Aug;19(4):316-323. DOI: 10.1017/S1092852913000394Morozova M.A., Lepilkina T.A., Rupchev G.E., Beniashvi- ly A.G., Burminskiy D.S., Potanin S.S., Bondarenko E.V., Ka- zey V.I., Lavrovsky Y., Ivachtchenko A.V. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. CNS Spectr. 2014 Aug;19(4):316-323. DOI: 10.1017/S1092852913000394

The authors declare that there are no conflicts of interest present.